Effects of Milrinone on Neonates after Patent Ductus Arteriosus Ligation: A Retrospective Nationwide Database Study
Neonatology · 2023
DOI: 10.1159/000533958 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neonatology, 2023. Verfasst von Hiroki Kitaoka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Ductus Arteriosus, Patent, Enterocolitis, Necrotizing, Bronchopulmonary Dysplasia, Retinopathy of Prematurity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Milrinone is administered after patent ductus arteriosus (PDA) ligation to prevent and treat postoperative hemodynamic instability (i.e., postligation cardiac syndrome). We aimed to explore the effectiveness of milrinone on in-hospital outcomes in infants who underwent PDA ligation using a nationwide inpatient database in Japan.
Methods
Using the Japanese Diagnosis Procedure Combination database, we identified patients who received milrinone after PDA ligation (n = 428) in neonatal intensive care units between July 2010 and March 2021 and those who did not (n = 3,392). We conducted a 1:4 propensity score-matched analysis with adjustment for background characteristics (e.g., gestational age, birth weight, comorbidities, preoperative treatments, and hospital background) to compare morbidities (bronchopulmonary dysplasia, intraventricular hemorrhage, necrotizing enterocolitis, and retinopathy of prematurity), mortality, total hospitalization costs, and other outcomes. For sensitivity analysis, we performed an overlap propensity score-weighted analysis.
Results
In-hospital morbidity, bronchopulmonary dysplasia, intraventricular hemorrhage, and necrotizing enterocolitis occurred in 58%, 48%, 9.5%, and 7.1% of patients, respectively; the in-hospital mortality was 5.4%. After 1:4 propensity score matching, no significant difference was observed regarding mortality (7.1 vs. 5.7%), in-hospital morbidity (55 vs. 50%), bronchopulmonary dysplasia (44 vs. 41%), intraventricular hemorrhage (7.8 vs. 9.1%), necrotizing enterocolitis (8.5 vs. 8.9%), retinopathy of prematurity (21 vs. 22%), or total hospitalization costs (median: approximately 86,000 vs. 82,000 US dollars) between milrinone users (n = 425) and nonusers (n = 1,698). Sensitivity analyses yielded consistent results.
Conclusions
Milrinone use after PDA ligation was not associated with improved in-hospital outcomes, such as mortality and morbidity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, The University of Tokyo Hospital, Tokyo, Japan.
- Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Zitieren
APA
Kitaoka, H., Konishi, T., Shitara, Y., Ito, A., Kashima, K., Fujita, A., Matsui, H., Kato, M., Takahashi, N., & Yasunaga, H. (2023). Effects of Milrinone on Neonates after Patent Ductus Arteriosus Ligation: A Retrospective Nationwide Database Study. Neonatology. https://doi.org/10.1159/000533958
Vancouver
Kitaoka H, Konishi T, Shitara Y, Ito A, Kashima K, Fujita A, et al. Effects of Milrinone on Neonates after Patent Ductus Arteriosus Ligation: A Retrospective Nationwide Database Study. Neonatology. 2023. doi:10.1159/000533958
BibTeX
@article{Kitaoka2023,
author = {Kitaoka, Hiroki and Konishi, Takaaki and Shitara, Yoshihiko and Ito, Atsushi and Kashima, Kohei and Fujita, Asahi and Matsui, Hiroki and Kato, Motohiro and Takahashi, Naoto and Yasunaga, Hideo},
title = {Effects of Milrinone on Neonates after Patent Ductus Arteriosus Ligation: A Retrospective Nationwide Database Study},
journal = {Neonatology},
year = {2023},
doi = {10.1159/000533958}
}
EUVIMED